摘要:
A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.
摘要:
Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18 F labeling compound represented by a predetermined general formula;allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18 F labeling compound;after the above step, purifying the 18 F labeling compound using a reverse phase solid phase extraction cartridge;and removing a protective group to obtain [ 18 F] flutemetamol.
摘要:
Compounds of formula (I), wherein the substituents are as defined in claim 1, and agrochemically acceptable salts thereof, can be used as insecticides.
摘要:
본 발명은 메모리 소자용 유기 도핑 재료, 이를 포함하는 비휘발성 메모리 소자 및 이의 제조방법을 제공한다. 본 발명의 메모리 소자용 유기 도핑 재료는 메모리 소자의 반도체에 도핑됨에 따라 상기 반도체가 비휘발성 메모리 특성을 나타내는 효과가 있다. 이에 따라, 강유전 특성을 갖는 게이트 절연체를 사용하지 않고 비휘발성 및 쌍안정성 메모리 거동 특성을 갖는 비휘발성 메모리 소자 및 이의 제조방법을 제공할 수 있는 효과가 있다.
摘要:
Compounds of the formula I in which R 1 , R 4 , R 6 , R, X 1 , X 2 , X 3 , X 4 , q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
摘要:
Provided is a long-lifetime organic light-emitting element having a good device lifetime characteristic. The organic light-emitting device includes: a pair of electrodes; and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a specific structure and a different kind of metal complex.
摘要:
The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
摘要:
Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.